NET PROFIT (x1000 EUR)
EMPLOYEES
XSpray Pharma AB (publ)
Closing information (x1000 EUR)
| Closing information | 2023/12 (consolidated) | 2021/12 (consolidated) | 2020/12 (consolidated) |
| Turnover |
0
|
0
|
0 |
| Financial expenses |
61
|
0
|
1 |
| Earnings before taxes |
-16,194
|
-9,455
|
-5,221 |
| EBITDA |
-16,378
|
-9,578
|
-5,326 |
| Total assets |
68,967
|
60,908
|
60,304 |
| Current assets |
19,630
|
27,581
|
32,978 |
| Current liabilities |
3,596
|
2,930
|
1,974 |
| Equity capital |
62,492
|
57,862
|
58,041 |
| - share capital |
2,817
|
2,022
|
1,882 |
| Employees (average) |
26
|
22
|
20 |
Financial ratios
| Fiscal year | 2023/12 (consolidated) | 2021/12 (consolidated) | 2020/12 (consolidated) |
| Solvency |
90.6%
|
95.0%
|
96.2% |
| Turnover per employee |
0
|
0
|
0 |
| Profit as a percentage of turnover | |||
| Return on assets (ROA) |
-23.4%
|
-15.5%
|
-8.7% |
| Current ratio |
545.9%
|
941.3%
|
1670.6% |
| Return on equity (ROE) |
-25.9%
|
-16.3%
|
-9.0% |
| Change turnover |
0
|
0
|
0 |
| Change turnover % | |||
| Chg. No. of employees |
4
|
2
|
3 |
| Chg. No. of employees % |
18%
|
10%
|
18% |
Total value of public sale
| Fiscal year | 2023/12 (consolidated) | 2021/12 (consolidated) | 2020/12 (consolidated) |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.